98%
921
2 minutes
20
Aim Of The Study: To analyze long-term epidemiological patterns and trends in the burden of infection and mortality due to viral hepatitis in Poland before and during the COVID-19 pandemic.
Material And Methods: Data for the burden of the most common viral hepatitis types (HAV, HBV ±HDV, HCV, and HEV) over 2009-2023 were extracted from the national registries in Poland. The joinpoint regression model was used to analyze trends in viral hepatitis infections and mortality.
Results: The burden of viral hepatitis infection and mortality in Poland changed between 2009 and 2023. Before the COVID-19 pandemic, the trend of newly diagnosed HAV infection was characterized by a sharp increase over 2015-2018 compared to the other types of hepatitis. At the beginning of the COVID-19 pandemic, the burden of infection and mortality among most types of hepatitis showed a change in the direction of the trend from negative to positive, which continued in subsequent years. A pronounced increasing trend for both infection and mortality occurred in the category of other viral hepatitis. Over the whole period of 2009-2023, there was only one decreasing trend for mortality due to HBV infection.
Conclusions: The findings of the study draw attention to the noticeable impact of the COVID-19 pandemic on the burden of viral hepatitis in Poland, which threatens to disrupt the beneficial direction of virus elimination. Trends of viral hepatitis infection and mortality require further monitoring. It is also necessary to increase preventive measures and improve access to diagnostics and the linkage to health care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403644 | PMC |
http://dx.doi.org/10.5114/ceh.2025.151703 | DOI Listing |
Sex Transm Dis
September 2025
Departments of Global Health, Medicine, and Epidemiology, University of Washington (JN Wasserheit), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (J Mermin and BP Stoner), and Rietmeijer Consulting (CA Rietmeijer).
mBio
September 2025
Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA.
Accurate timing estimates of when participants acquire HIV in HIV prevention trials are necessary for determining antibody levels at acquisition. The Antibody-Mediated Prevention (AMP) Studies showed that a passively administered broadly neutralizing antibody can prevent the acquisition of HIV from a neutralization-sensitive virus. We developed a pipeline for estimating the date of detectable HIV acquisition (DDA) in AMP Study participants using diagnostic and viral sequence data.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
Hepatitis B virus (HBV) infection is a global health challenge, with the World Health Organization (WHO) targeting its elimination by 2030. Jordan lacks sufficient data on HBV epidemiology, including prevalence, incidence and clearance. This study addresses these gaps through a retrospective analysis of HBV testing data from 40,268 individuals collected at Biolab Diagnostic Laboratories (2010-2024).
View Article and Find Full Text PDFBackground: Cytomegalovirus (CMV) viremia is a critical concern and known by the presence of the virus DNA in the blood, which poses sever risks and develops many complications in immuno-compromised patients. When CMV is untreated, it can cause pneumonitis, colitis, hepatitis, and encephalitis. Current diagnosis relies on molecular methods with qPCR as the preferred method.
View Article and Find Full Text PDF